These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1482 related items for PubMed ID: 18230792

  • 1. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M.
    J Natl Cancer Inst; 2008 Feb 06; 100(3):184-98. PubMed ID: 18230792
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
    Kancha RK, Grundler R, Peschel C, Duyster J.
    Exp Hematol; 2007 Oct 06; 35(10):1522-6. PubMed ID: 17889720
    [Abstract] [Full Text] [Related]

  • 4. Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia.
    Safaian NN, Czibere A, Bruns I, Fenk R, Reinecke P, Dienst A, Haas R, Kobbe G.
    Leuk Res; 2009 Feb 06; 33(2):348-50. PubMed ID: 18573526
    [Abstract] [Full Text] [Related]

  • 5. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
    Lopes de Menezes DE, Peng J, Garrett EN, Louie SG, Lee SH, Wiesmann M, Tang Y, Shephard L, Goldbeck C, Oei Y, Ye H, Aukerman SL, Heise C.
    Clin Cancer Res; 2005 Jul 15; 11(14):5281-91. PubMed ID: 16033847
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.
    Colovic N, Tosic N, Aveic S, Djuric M, Milic N, Bumbasirevic V, Colovic M, Pavlovic S.
    Ann Hematol; 2007 Oct 15; 86(10):741-7. PubMed ID: 17579862
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
    Zhang W, Gao C, Konopleva M, Chen Y, Jacamo RO, Borthakur G, Cortes JE, Ravandi F, Ramachandran A, Andreeff M.
    Clin Cancer Res; 2014 May 01; 20(9):2363-74. PubMed ID: 24619500
    [Abstract] [Full Text] [Related]

  • 10. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N, Torres LA, Rodriguez-Ariza A, Valverde-Estepa A, Lopez-Sanchez LM, Ruiz-Limon P, Perez-Sanchez C, Carretero RM, Velasco F, López-Pedrera C.
    Exp Hematol; 2010 Aug 01; 38(8):641-52. PubMed ID: 20380868
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.
    Baker SD, Zimmerman EI, Wang YD, Orwick S, Zatechka DS, Buaboonnam J, Neale GA, Olsen SR, Enemark EJ, Shurtleff S, Rubnitz JE, Mullighan CG, Inaba H.
    Clin Cancer Res; 2013 Oct 15; 19(20):5758-68. PubMed ID: 23969938
    [Abstract] [Full Text] [Related]

  • 13. A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia.
    Wang P, Xiao X, Zhang Y, Zhang B, Li D, Liu M, Xie X, Liu C, Liu P, Ren R.
    J Hematol Oncol; 2021 Jul 03; 14(1):105. PubMed ID: 34217323
    [Abstract] [Full Text] [Related]

  • 14. [FLT3 mutations in children with acute myeloid leukemia: a single center study].
    Ruan M, Wang YQ, Zhang L, Liu TF, Liu F, Liu XM, Zhang JY, Zou Y, Chen YM, Zhu XF.
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Nov 03; 13(11):863-6. PubMed ID: 22099191
    [Abstract] [Full Text] [Related]

  • 15. Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.
    Parmar A, Marz S, Rushton S, Holzwarth C, Lind K, Kayser S, Döhner K, Peschel C, Oostendorp RA, Götze KS.
    Cancer Res; 2011 Jul 01; 71(13):4696-706. PubMed ID: 21546568
    [Abstract] [Full Text] [Related]

  • 16. FLT3/ ITD regulates leukaemia cell adhesion through α4β1 integrin and Pyk2 signalling.
    Katsumi A, Kiyoi H, Abe A, Tanizaki R, Iwasaki T, Kobayashi M, Matsushita T, Kaibuchi K, Senga T, Kojima T, Kohno T, Hamaguchi M, Naoe T.
    Eur J Haematol; 2011 Mar 01; 86(3):191-8. PubMed ID: 21114537
    [Abstract] [Full Text] [Related]

  • 17. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
    Man CH, Fung TK, Ho C, Han HH, Chow HC, Ma AC, Choi WW, Lok S, Cheung AM, Eaves C, Kwong YL, Leung AY.
    Blood; 2012 May 31; 119(22):5133-43. PubMed ID: 22368270
    [Abstract] [Full Text] [Related]

  • 18. A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations.
    Kiyoi H, Shiotsu Y, Ozeki K, Yamaji S, Kosugi H, Umehara H, Shimizu M, Arai H, Ishii K, Akinaga S, Naoe T.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4575-82. PubMed ID: 17671144
    [Abstract] [Full Text] [Related]

  • 19. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C, Steur C, Mizuki M, Schwäble J, Brandts C, Berdel WE, Serve H.
    Dtsch Med Wochenschr; 2002 Oct 18; 127(42):2195-200. PubMed ID: 12397548
    [Abstract] [Full Text] [Related]

  • 20. Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia.
    Liang DC, Shih LY, Hung IJ, Yang CP, Chen SH, Jaing TH, Liu HC, Chang WH.
    Cancer; 2002 Jun 15; 94(12):3292-8. PubMed ID: 12115363
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 75.